Search

Background and Aims: Adverse pregnancy outcomes (APO) have been related to increased cardiovascular (CV) risk and mortality in later life. Underlying pathomechanisms for the development of CV disease in these women are not yet fully understood. In this study, we aimed to investigate the relationship between APO and individual CV risk profiles in later life., Methods: We used cross-sectional data from 10,000 participants enrolled in the Hamburg City Health Study (HCHS). We analysed self-reported APO, CV risk factors and health status, including biomarkers, electrocardiogram, echocardiography and vascular ultrasound. To examine associations, Wilcoxon rank sum test and Pearson's χ 2 -test were performed. Multivariable-adjusted regression models were calculated to determine associations., Results: N = 1970 women who reported pregnancies were included. Median age was 63 years, 8.7 % reported gestational hypertension (gHTN), 18 % excessive weight gain and 2.4 % gestational diabetes. Ten percent had delivered newborns with birth weight <2.5 kg, 14 % newborns with birth weight >4 kg. In multivariable-adjusted models, significant associations between APO, CV risk profiles and cardiac remodeling were identified. gHTN correlated with higher body mass index (BMI) (Beta 1.68, CI 95 % 0.86-2.50; p < 0.001), hypertension (OR 4.58, CI 95 % 2.79-7.86; p < 0.001), left ventricular remodeling (e.g. left ventricular mass index (Beta 4.46, CI 95 % 1.05-7.87; p = 0.010)) and myocardial infarction (OR 3.27, CI 95 % 0.94-10.07; p = 0.046)., Conclusions: In this population-based sample, APO were associated with CV risk profiles and cardiac remodeling in later life, suggesting early manifestations of future CV risk during pregnancy. Prospective data is needed for individual risk stratification in women with APO., Competing Interests: Declaration of competing interest All participating institutes and departments from the University Medical Center Hamburg-Eppendorf contribute with scaled budgets to the overall funding of the Hamburg City Health Study (HCHS). Moreover, HCHS has received funding from the Innovative medicine initiative (IMI) under Grant No. 116074 (European public-private-partnership), Fondation Leducq (Grant Number 16 CVD 03), euCanSHare (Grant Agreement No. 825903-euCanSHare H2020) and the Deutsche Forschungsgemeinschaft (DFG project Grant TH1106/5-1; AA93/2-1). The HCHS is further supported by Joachim Herz Foundation; Deutsche Gesetzliche Unfallversicherung (DGUV); Deutsches Krebsforschungszentrum (DKFZ); Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK); Deutsche Stiftung für Herzforschung; Seefried Stiftung; Bayer; Amgen, Novartis; Schiller; Siemens; Topcon, Unilever and by donations from the “Förderverein zur Förderung der HCHS e.V.”, and TePe® (2014). Sponsor funding has in no way influenced the content, conclusions or management of this study. E.U., K.B., G.A., P.S., C.V.R. and C.A.B. have not received any project related funding. N.M. reports personal fees from Abbott Laboratories, outside the submitted work. C.M. receives study-specific funding from the German Center for Cardiovascular Research (DZHK; Promotion of women scientists’ programme; FKZ 81X3710112), the Deutsche Stiftung für Herzforschung, the Dr. Rolf M. Schwiete Stiftung, NDD, and Loewenstein Medical unrelated to the current work. C.M. has received speaker fees from AstraZeneca, Novartis, Boehringer Ingelheim/Lilly, Bayer, Pfizer, Sanofi, Aventis, Apontis, Abbott outside this work. C.M. has participated in a Boehringer Ingelheim heart failure advisory board. S.B. is supported by the Innovative medicine initiative (IMI) under Grant No. 116074, the Fondation Leducq under Grant Number 16 CVD 03, Siemens, Bayer, Astra Zeneca, Deutsche Gesetzliche Unfallversicherung (DGUV) and Novartis for project related analyses. B.C.Z. has received an unrestricted project-related funding from BASF and Unilever for implementing a food frequency questionnaire into the interviews of the Hamburg City Health Study and reports fees from Jenapharm GmbH and BESINS Heathcare for lectures outside this work. R.B.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union's Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). Wolfgang Seefried project funding German Heart Foundation. R.B.S. has received lecture fees and advisory board fees from BMS/Pfizer and Bayer outside this work. E.U., N.M., K.B., P.S., C.V.R, G.A, C.M., C.A.B, S.B., B.C.Z. and R.B.S. report no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)